Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: SnowShredder who wrote (1900)	4/7/1998 3:21:00 AM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 4676

Where'd... There is not and will not be (at least in next 20 years, imo) cancer monotherapy regime which can address all aspect for successful cancer drug. Combination of two or three different drug which are complementary and synergistic (where one drug potentate others effects) in anticancer activity is for now correct approach. So, antisense (whatever is their primary target: oncogene, signal induction, grow factor, angiogenesis,...) are not designee as monotherapy. If they can (lady with ovarian cancer show that it can) increase therapy regime efficiency to be warranted and where combine side effects are tolerable, they will have place on market. When monotherapy (antisense) show promised efficiency in PII, combination therapy is next step. Very few late stage trials are still designed as monotherapy, I guess not many are in practice. mz